Postmenopausal hormone therapy and the risk for uterine cancers

Postmenopausal hormone therapy and the risk for uterine cancers


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 3,651

Availability: Out of stock


Delivery :

5% Cashback on all Orders paid using MobiKwik Wallet T&C

Free Krispy Kreme Voucher on all Orders paid using UltraCash Wallet T&C
Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

Large differences exist between countries in the context and use of postmenopausal hormone therapies. Differences also exist in genes, diet and lifestyle, which all affect the risk for cancers. I studied the effects of different estrogen-progestagen therapies (EPT) for the risk of endometrial and cervical cancer as well as uterine sarcoma in nationwide studies on postmenopausal Finnish women. The use of postmenopausal EPT is one determinant for the occurrence of uterine cancers. Continuous combined regimens decrease and sequential regimens increase the risk for endometrial cancer; these data support earlier findings. The following new observations were made; oral and transdermal routes of administration or various types of progestagens do not modify these effects. A consistent decrease in the incidence of squamous cervical malignancies was seen in EPT users. In contrast, the incidence of cervical adenocarcinoma was increased. The risk for uterine sarcomas is increased if EPT has been used for longer times. These data are of importance for the potential users of EPT and for physicians prescribing such regimens.

Product Specifications
SKU :COC30382
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-07-31
0 Review(s)